News

All the latest developments
from the institute

Lilly Website Banner

New partnership with Lilly to accelerate search for new treatments for dementia

We are thrilled to announce a new partnership with pharmaceutical company Lilly, which will see us work together to identify new potential treatments for dementia.

Read Article
Spn 1 Fus Copy

Breakthrough disease mechanism behind Amyotrophic Lateral Sclerosis (ALS) uncovered

A team of researchers led by Dr Marc-David Ruepp, Group Leader from UK DRI at King’s College London have uncovered a new role for RNA in the development of Amyotrophic Lateral Sclerosis (ALS). Their discovery provides the molecular basis for a disease cascade that is initiated by the ALS-linked protein FUS and could serve as a platform from which to generate new therapeutics for those living with the condition.

Read Article
Astrocyte Co Culture Duff

Right drug, right patient, right time: Unravelling clinical trial failures in dementia with Professor Karen Duff

It’s been over a century since the discovery of Alzheimer’s disease, the most common form of dementia, and yet we are still without drugs that can slow or halt the condition that afflicts millions worldwide. While we have seen huge strides made in other major health challenges that face society, such as cancer, therapeutic solutions still remain elusive for dementia, which is now the leading cause of death in the UK. To pull apart the issue, we sat down with Professor Karen Duff to find out more about the obstacles facing the dementia field, her research into the fundamental biology behind the diseases, and where we go from here.

Read Article
25 Equipment Alt

How technology is driving forward dementia research: A Q&A with Tools & Technology Platform Manager, Sam Jackson

With each passing decade, we are discovering more about the diseases that present immense health challenges to our society. Although brilliant ideas and people are core to these developments, the advancement of technology has played a major role and allowed us to drill down into the complexities that surround these conditions. To take full advantage of these tools, a co-ordinated approach is required to ensure all researchers have access to the equipment and expertise they need. We caught up with Dr Sam Jackson, Tools and Technology Platform Manager at UK DRI, to find out more about how technology will form a key component of the institute’s strategy going forward.

Read Article
Highly Cited Banner

UK DRI researchers amongst most highly cited in world

We are proud to announce that nine UK DRI researchers have featured in this year’s Highly Cited Researcher 2020 list from Clarivate. The annual ranking identifies researchers who have demonstrated significant influence in their chosen field or fields through the publication of multiple highly cited papers during the last decade.

Read Article
Lifearc Banner 2

UK DRI appoints LifeArc to support translation of discoveries into treatments

We are excited to announce that the UK DRI has appointed independent medical research charity LifeArc to provide expertise to accelerate the translation of our researchers’ discoveries into treatments that will transform the lives of those affected by dementia.

Read Article
Bna2021 Online Website Copy

Registration and abstract submission open for BNA2021 Festival of Neuroscience

Registration and abstract submission are now open for British Neuroscience Association’s (BNA) Festival of Neuroscience (BNA2021), taking place virtually from 12-15 April 2021. The UK DRI is delighted to join forces with BNA as Festival Partner – presenting the perfect opportunity to bring together the wider dementia research and neuroscience communities.

Read Article
Mri Atrophy Example

UK DRI researchers discover way to predict neurodegeneration following head injury

A team of researchers from the UK DRI have, for the first time, been able to accurately predict the extent of chronic neurodegeneration in people who have experienced traumatic brain injury, using an advanced type of MRI scanning. The results could help identify suitable candidates for clinical treatment trials, with the aim of preventing dementia post-injury.

Read Article
Connectome 2020 Logo Image Virtual

Connectome 2020: UK DRI researchers come together virtually for annual conference

Earlier this month, our annual conference brought together UK DRI researchers, support staff and students to share scientific progress. Now in its third year, Connectome is designed to align the institute’s vision, encourage new collaborations and spark ideas that take our research to the next level.

Read Article
Amyloid Tau Nih

Targeting cell types in dementia: The future of drug discovery?

Over the past decade, advances in genetic technology have allowed scientists to investigate human disease at an unprecedented level, bringing the prospect of new and effective treatments closer than ever before. One researcher taking advantage of these new opportunities is Dr Nathan Skene, Group Leader at UK DRI at Imperial, who is using cutting-edge genetic and statistical approaches to gain greater understanding of the cell types responsible for dementia. We caught up with Nathan to find out more about his research, how genetics is revolutionising our understanding of disease and his hope for treatments in the future.

Read Article
Bna2021 Online Website Copy

Plenary speakers revealed for BNA Festival of Neuroscience in April 2021

The British Neuroscience Association (BNA) and UK DRI, as Festival Partner, are excited to announce a line-up of top international plenary speakers for BNA2021 Festival of Neuroscience taking place virtually from 12-15 April 2021. For the UK DRI’s scientific stream ‘Ageing and dementia’, UK DRI Director Prof Bart De Strooper, will be delivering a plenary lecture on the cellular phase of Alzheimer’s disease.

Read Article
Sleep Illustration

In conversation with Dr Marieke Hoekstra, UK DRI at Imperial

Dr Marieke Hoekstra is a Research Associate studying the mechanisms underlying the association between dementia and sleep/circadian disturbances. She joined the UK DRI at Imperial in May 2019 and is part of Marco Brancaccio's research group​. In this Q&A, Xiaoqi Zhu, a PhD student based in the lab of Dr Nir Grossman, speaks to Marieke about her career so far, her research into sleep and dementia, and new techniques in her field of research.

Read Article
Blue Heaxagons Digital Shutterstock Fotomay Copy

Launch of UK DRI Portal and Research Collaboration Service

We are today excited to launch our brand-new UK DRI Portal to facilitate the sharing of information, news and events across the institute. The Portal, an intranet for all UK DRI staff, will sit at the centre of the recently rolled-out Research Collaboration Service - a suite of cloud-based software platforms designed to digitally unite researchers and support staff across the seven research centres.

Read Article
Touchscreen Ha Edits

UK DRI joins forces with cognitive and behavioural neuroscience research initiative, BrainsCAN

We are delighted to announce a new partnership with the cognitive and behavioural neuroscience research initiative, BrainsCAN, to advance our understanding of higher cognitive processing in rodents through novel touchscreen technology and methods. The knowledge gained has the potential to assist our development of treatments for dementia.

Read Article
Blood Sample Angellodeco Shutterstock Copy

UK DRI and Eisai award funding to test new blood biomarker for Parkinson’s disease

UK DRI is thrilled to announce that Group Leader Dr Tim Bartels, UK DRI at UCL, has been awarded funding to test a promising new biomarker for Parkinson’s disease. Working collaboratively with Eisai, one of the world’s leading research based pharmaceutical companies, a newly hired postdoctoral researcher will build on preliminary work from the group with the aim of improving diagnosis of the condition.

Read Article
Alzheimers Care

UK DRI takes stock on World Alzheimer’s Day 2020

On World Alzheimer’s Day, 21 September 2020, the UK DRI acknowledges all those impacted by Alzheimer’s disease and other causes of dementia. Our 600+ researchers across our seven sites are working hard to uncover the causes of dementia and identify promising treatments.

Read Article
Shutterstock 1670462338 Copy

Team behind robotic Covid-19 testing platform publish new workflow details and two rapid assays to help others scale up testing efforts

The UK DRI team behind a high-throughput robotic coronavirus testing platform that was developed in just nine days in April, have made the full details of their setup and workflow available to others, in an effort to support the scaling-up of testing capacity across the UK.

Read Article
Uk Dri Square Black Small

UK DRI scientists pay tribute to Professor Peter Davies

Our community is deeply saddened to hear that Professor Peter Davies has passed away after a long battle with cancer. UK DRI colleagues have been sharing tributes and memories of working with Peter.

Read Article
180724 Grossman Nir Brain Stimulation 006

UK DRI researcher awarded $1.5 million to trial deep brain stimulation therapy for Alzheimer’s disease

A team of researchers, led by Group Leader Dr Nir Grossman, UK DRI at Imperial, has been awarded $1.5 million by the USA-based Alzheimer's Association’s Part the Cloud fund, to accelerate the application of a new non-invasive deep brain stimulation therapy for people with Alzheimer’s disease.

Read Article
Helix Dna Adike Shutterstock Red

Genetic study from team based at UK DRI at Cardiff probes origins of Parkinson’s disease

Researchers led by Prof Caleb Webber, Group Leader at UK DRI at Cardiff, have studied the genes of more than 6,000 cells from a brain region called the substantia nigra, which is damaged in Parkinson’s disease. The team found that genes associated with increased risk of developing the condition were more active in dopaminergic neurons, suggesting that these cells should be targeted for future therapeutic intervention.

Read Article